Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal
valued at up to EUR108 Million

   Biophytis / Key word(s): Miscellaneous/Miscellaneous
   Biophytis grants Blanver exclusive rights to BIO101 in Latin
   America in deal valued at up to EUR108 Million
   20-Jun-2024 / 07:00 CET/CEST
     ____________________________________________________________

   
   Biophytis grants Blanver exclusive rights to BIO101 in Latin
   America in deal valued at up to EUR108 Million

     * Biophytis to receive upfront and milestones payments for a
       total amount up to EUR108 million, as well as double-digit
       royalties on future sales of the product
     * Agreement covers commercialization of BIO101 in Latin America

     * Biophytis and Blanver intend to collaborate on manufacturing
       and joint clinical development for Latin America

   Paris (France) and Cambridge (Massachusetts, USA), June, 20th,
   2024 - 07:00 am CET - Biophytis SA (Euronext Growth Paris :
   ALBPS), ("Biophytis" or the "Company"), a clinical-stage
   biotechnology company specialized in the  development of
   therapeutics for age-related diseases, today announces the
   signature of an exclusive license agreement with Blanver, one of
   the leading and most trusted pharmaceutical company in Brazil,
   for BIO101 (20-Hydroxyecdysone) in Latin American including, but
   not limited to Brazil, Mexico, Argentina and Colombia.

   The agreement provides that Blanver will be responsible for the
   registration, marketing and commercialization of BIO 101
   (20-Hydroxyecdysone) in its various indications: obesity,
   respiratory infections due to Covid-19, sarcopenia and Duchenne
   Muscular Dystrophy (DMD) - once Biophytis has successfully
   completed the planned clinical development programmes for its
   drug candidate. With 40 years of history, Blanver has become an
   expert in infectious diseases, osteoporosis and metabolic
   disorders, which is a perfect match with Biophytis. In addition
   of Brazil, Blanver has an extensive network of unique
   distributors that covers the whole Latin America region.

   Under the terms of this partnership, Biophytis will be able to
   receive up to EUR108 million including an upfront payment and
   further additional payments if certain objectives are achieved.
   Biophytis is also eligible to receive double-digit royalties on
   net sales of BIO101 (20-Hydroxyecdysone) generated in the
   collaboration territory, after obtaining future marketing
   authorisations.

   This collaboration in one of the main pharma regions in the
   world, underscores the potential of BIO101 (20-Hydroxyecdysone)
   which is based on the positive clinical results already obtained
   in several indications.

   Stanislas Veillet, CEO of Biophytis, stated: "I warmly welcome
   this new partnership which is a key milestone that will enable
   Biophytis to further deploy its strategic roadmap, especially in
   obesity. This is a unique opportunity for both companies and
   comes at a crucial time as Brazil is the most fast-growing
   pharmaceutical market, representing more than $23 billion in
   2023. In the LATAM region, 100 million of patients are suffering
   from obesity. We look forward to continuing our clinical and
   regulatory development work with Blanver over the coming months
   and to exploring with them early market access opportunities for
   our most advanced indications. Together, we aim to deliver
   solutions to patients and physicians over the years ahead."

   Sergio Frangioni, CEO of Blanver, commented: "Innovation is part
   of the Blanver DNA, and we are thrilled to partner with
   Biophytis, to bring this unique medicine in Latin America. We are
   very confident that the clinical study of the novel BIO101
   (20-hydroxyecdysone), will show encouraging results, which will
   support the medical community to obesity, their effects and bring
   health and quality of life to so many patients who suffer from
   this condition."

* * * *


About BIOPHYTIS

   Biophytis SA is a clinical-stage biotechnology company
   specializing in the development of drug candidates for
   age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug
   candidate, is a small molecule in development for muscular
   (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
   respiratory (Covid-19 phase 2-3 completed) and metabolic diseases
   (obesity, phase 2 to be started). The company is based in Paris,
   France, and Cambridge, Massachusetts. The Company's ordinary
   shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
   FR0012816825). For more information, visit www.biophytis.com

About BLANVER

   Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company,
   founded in 1984, focused on R&D, manufacture and sale of
   innovative medicines and active pharmaceutical ingredients
   (APIs). The company plays in the segments of HIV, Hepatitis,
   Oncology, Hematology and Rare Disease, providing high quality
   products for expanding the population's access to medicines
   through partnerships with the Ministry of Health and official
   laboratories. Blanver is committed in always looking for
   innovations that will improve people's health and quality of
   life.

Forward-looking statements

   This press release contains forward-looking statements.
   Forward-looking statements include all statements that are not
   historical facts. In some cases, you can identify these
   forward-looking statements by the use of words such as
   "outlook,"  "believes,"  "expects,"  "potential,"  "continues,"
   "may,"  "will,"  "should,"  "could,"   "seeks," "predicts,"
   "intends," "trends," "plans," "estimates," "anticipates" or the
   negative version of these   words or other comparable words. Such
   forward-looking statements are based on assumptions that
   Biophytis considers to be reasonable.  However, there can be no
   assurance that the statements contained in such forward-looking
   statements will be verified, which are subject to various risks
   and uncertainties. The forward- looking statements contained in
   this press release are also subject to risks not yet known to
   Biophytis or not currently considered material by Biophytis.
   Accordingly, there are or will be important factors that could
   cause actual outcomes or results to differ materially from those
   indicated in these statements. Please also refer to the "Risk and
   uncertainties the Company is to face» section from the Company's
   2023 Financial Report available on BIOPHYTIS website
   (www.biophytis.com) and as exposed in the "Risk Factors" section
   of form 20-F as well as other forms filed with the SEC
   (Securities and Exchange Commission, USA). We undertake no
   obligation to publicly update or review any forward-looking
   statement, whether as a result of new information, future
   developments or otherwise, except as required by law.

Biophytis contacts


Investor relations


Nicolas Fellmann, CFO

Investors@biophytis.com


Pharma partners


Edouard Bieth, CBO

edouard.bieth@biophytis.com


Media


Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50


Blanver contacts


Investor relations


Sergio José Frangioni, CEO


Media


Herbert Silva: Herbert.silva@blanver.com.br

Lilia Lima de Almeida: lilia.almeida@blanver.com.br

____________________________________________________________

   Dissemination of a Financial Wire News, transmitted by EQS Group.
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   Language:    English
   Issuer:      Biophytis
                14 avenue de l´Opéra
                75001 Paris
                France
   Internet:    https://www.biophytis.com
   ISIN:        US09076G1040, FR0012816825
   EQS News ID: 1929271

   End of Announcement - EQS News Service
     ____________________________________________________________

1929271 20-Jun-2024 CET/CEST